Colleen Barthol

Colleen Barthol

Auto-generated profile, based on publicly available information

Colleen Barthol

Clinical Pharmacy Specialist

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Hospital Pharmacy
Verified
Journal Article
Closed access
GCG. Christina Caballero
G. Christina Caballero
DHDarrel W. Hughes
Darrel W. Hughes
PMPamela R. Maxwell
Pamela R. Maxwell
KGKay Green
Kay Green
CGConrado D. Gamboa
Conrado D. Gamboa
CBColleen A. Barthol
Colleen A. Barthol
Background: Phenytoin is standard of care for seizure prophylaxis following traumatic brain injury (TBI). Levetiracetam, an alternative antiepileptic drug, is utilized for seizure prophylaxis despite limited data supporting its use. Objective: Our primary outcome was post-TBI seizure activity measured by electroencephalogram (EEG) for levetiracetam versus phenytoin. Secondary outcomes were length of intensive care unit (ICU) stay, requirement for additional antiepileptic drugs (AED), and drug and monitoring costs. Methods: A retrospective review was performed of patients admitted to neurosurgical or surgical trauma ICU. Adult patients with at least 1 day of EEG monitoring were included. Patients were excluded if they had history of epilepsy, prior TBI, less than 48 hours of AED therapy, or additional AED prior to EEG monitoring. Results: A total 90 patients met inclusion criteria, with 18 receiving levetiracetam and 72 receiving phenytoin. Prevalence of EEG-confirmed seizure activity was similar between the levetiracetam and phenytoin groups (28% vs 29%; P = .99). ICU length of stay (13 vs 18 days; P = .28), time to EEG-confirmed seizure activity (4 vs 6 days; P = .24), and duration of seizure prophylaxis (9 vs 14 days; P = .18) were also similar. The median daily cost of levetiracetam therapy was $43 compared to $55 for phenytoin therapy and monitoring ( P = .08). When all anticonvulsant therapy and monitoring were included, costs were lower for the levetiracetam group ($45 vs $83; P = .02). Conclusion: Levetiracetam may provide an alternative treatment option for seizure prevention in TBI patients in the ICU. Total antiepileptic drug and monitoring costs were lower for levetiracetam patients.

1 January 2021 in Epilepsy & Behavior Reports
Verified
Journal Article
Open access
JDJonathan P. Donnelly
Jonathan P. Donnelly
NKNidhi Kasatwar
Nidhi Kasatwar
SHShaheryar Hafeez
Shaheryar Hafeez
ASAli Seifi
Ali Seifi
AGAndrea Gilbert
Andrea Gilbert
CSC. Ákos Szabó
C. Ákos Szabó
• New onset refractory status epilepticus (NORSE) is a recently defined clinical entity. • No proven effective therapy for NORSE currently exists. • Proposed mechanisms include autoimmunity or inflammatory cascade within the brain leading to propagation of seizures. • Agents targeting the cytokines involved in this cascade are being investigated as potential treatments. • Tocilizumab, an IL-6 inhibitor, successfully treated our patient after nine weeks of refractory seizure activity.

21 May 2022 in Critical Care Research and Practice
Verified
Journal Article
Open access
PDF file
BDBradley A. Dengler
Bradley A. Dengler
OKOliver Karam
Oliver Karam
CBColleen A. Barthol
Colleen A. Barthol
ACAaron Chance
Aaron Chance
LSLaura E. Snider
Laura E. Snider
SHShaheryar Hafeez
Shaheryar Hafeez
Background. Increased intracranial pressure (ICP) and hypotension have long been shown to lead to worse outcomes in the severe traumatic brain injury (TBI) population. Adequate sedation is a fundamental principle in TBI care, and ketamine is an attractive option for sedation since it does not commonly cause systemic hypotension, whereas most other sedative medications do. We evaluated the effects of ketamine boluses on both ICP and cerebral perfusion pressure (CPP) in patients with severe TBI and refractory ICP. Methods. We conducted a retrospective review of all patients admitted to the neurointensive care unit at a single tertiary referral center who had a severe traumatic brain injury with indwelling intracranial pressure monitors. We identified those patients with refractory intracranial pressure who received boluses of ketamine. We defined refractory as any sustained ICP greater than 20 mmHg after the patient was adequately sedated, serum Na was at goal, and CO2 was maintained between 35 and 40 mmHg. The primary outcome was a reduction in ICP with a subsequent increase in CPP. Results. The patient cohort consisted of 44 patients with a median age of 30 years and a median presenting Glasgow Coma Scale (GCS) of 5. The median reduction in ICP after administration of a ketamine bolus was −3.5 mmHg (IQR −9 to +1), and the postketamine ICP was significantly different from baseline ( ). Ketamine boluses led to an increase in CPP by 2 mmHg (IQR −5 to +12), which was also significantly different from baseline ( ). Conclusion. In this single-institution study of patients with severe traumatic brain injury, ketamine boluses were associated with a reduction in ICP and an increase in CPP. This was a retrospective review of 43 patients and is therefore limited in nature, but further randomized controlled trials should be performed to confirm the findings.

25 January 2022 in Cureus
Verified
Journal Article
Open access
MUMargaret Upchurch
Margaret Upchurch
JDJonathan P. Donnelly
Jonathan P. Donnelly
EDEmily Deremiah
Emily Deremiah
CBColleen Barthol
Colleen Barthol
SHShaheryar Hafeez
Shaheryar Hafeez
ASAli Seifi
Ali Seifi
Hereditary coproporphyria (HCP) is a rare disorder caused by a deficiency of an enzyme, coproporphyrinogen oxidase, in the heme synthetic pathway. This disease has a highly variable clinical presentation with acute attacks of neurologic symptoms that can last from days to months. Rarely, it and other acute porphyrias may cause ascending paralysis, which is difficult to distinguish from Guillain-Barré syndrome (GBS). Acute attacks can be triggered by factors that increase the synthesis of heme, such as hormonal changes, certain medications, dietary changes, and infections. We report a 26-year-old female with HCP who presented with acute ascending flaccid paralysis and respiratory failure after coronavirus disease 2019 (COVID-19) infection and was initially misdiagnosed and treated for GBS. She was transferred to our neurosciences intensive care unit, where the diagnosis of acute porphyria was established. Initial improvement occurred during treatment for several weeks with hemin (Panhematin®) and continued with givosiran (Givlaari®), which was recently introduced for the prevention of acute attacks. We suggest that acute porphyria should be part of the differential diagnosis when GBS is suspected. To our knowledge, this is the first report of an attack of acute hepatic porphyria (AHP) that developed after a COVID-19 infection and the first with advanced paresis to be treated with givosiran. Her response suggests that givosiran may contribute to recovery from advanced neurological manifestations of acute porphyrias.

20 November 2020
Verified
Book Chapter
Closed access
PDF file
CBColleen Barthol
Colleen Barthol